Jan 07, 2015 7:35am EST Matinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
Dec 23, 2014 8:05am EST Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
Nov 24, 2014 7:05am EST Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
Nov 12, 2014 7:35am EST Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
Nov 04, 2014 7:35am EST Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
Oct 29, 2014 7:35am EDT Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
Oct 20, 2014 8:05am EDT Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
Sep 30, 2014 7:35am EDT Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
